Orexigen Therapeutics Inc. said Monday that its obesity-drug candidate Contrave met its main goals in three late-stage clinical trials, and also surpassed a Food and Drug Administration requirement for effectiveness.
Patients who took Contrave had significantly greater weight loss than those who took a placebo, and the drug also reduced other risk factors like waist circumference, the company said. For diabetes patients, the drug also reduced blood sugar levels.
Posts
0 comments:
Post a Comment